Table 2.
Observed 5-year survival and adjusted HR with 95% CI for oesophageal adenocarcinoma and oesophageal squamous cell carcinoma in 1990–2013, with follow-up until 2017
| Covariate | Category | Oesophageal adenocarcinoma | Oesophageal squamous-cell carcinoma | ||||
| Patients Number (%) | 5-year survival (95% CI) | HR (95% CI)* | Patients Number (%) | 5-year survival (95% CI) | HR (95% CI)* | ||
| All patients | |||||||
| Calendar period | 1990–1994 | 332 (9) | 10 (7 to 14) | 1.17 (1.02 to 1.33) | 1148 (25) | 8 (6 to 9) | 1.19 (1.07 to 1.31) |
| 1995–1999 | 557 (15) | 11 (8 to 13) | 1.11 (0.99 to 1.24) | 1014 (22) | 10 (8 to 12) | 1.11 (1.00 to 1.23) | |
| 2000–2004 | 860 (23) | 11 (9 to 13) | 1.07 (0.97 to 1.18) | 931 (20) | 7 (6 to 9) | 1.13 (1.01 to 1.25) | |
| 2005–2009 | 1054 (28) | 12 (10 to 14) | 1.04 (0.94 to 1.16) | 861 (19) | 10 (8 to 12) | 1.07 (0.96 to 1.19) | |
| 2010–2013 | 991 (26) | 13 (11 to 15) | 1 (reference) | 677 (15) | 11 (9 to 13) | 1 (reference) | |
| Age (years) | <60 | 686 (18) | 18 (15 to 21) | 1 (reference) | 787 (17) | 14 (12 to 17) | 1 (reference) |
| 60–69 | 1079 (28) | 16 (13 to 18) | 1.05 (0.94 to 1.16) | 1344 (29) | 12 (10 to 14) | 1.11 (1.01–1.22) | |
| 70–79 | 1166 (31) | 12 (10 to 13) | 1.25 (1.13 to 1.39) | 1588 (34) | 8 (7 to 9) | 1.38 (1.26 to 1.51) | |
| ≥80 | 863 (23) | 2 (1 to 3) | 1.99 (1.78 to 2.23) | 912 (20) | 2 (1 to 2) | 2.06 (1.86 to 2.28) | |
| Sex | Male | 3098 (82) | 12 (11 to 13) | 1 (reference) | 2938 (63) | 8 (7 to 9) | 1 (reference) |
| Female | 696 (18) | 10 (8 to 12) | 1.04 (0.95 to 1.14) | 1693 (37) | 11 (9 to 12) | 0.83 (0.78 to 0.89) | |
| Comorbidity score | 0 | 2096 (55) | 14 (13 to 15) | 1 (reference) | 2367 (51) | 11 (10 to 13) | 1 (reference) |
| 1 | 1115 (29) | 11 (9 to 12) | 1.11 (1.03 to 1.20) | 1598 (35) | 7 (6 to 9) | 1.15 (1.08 to 1.23) | |
| ≥2 | 583 (15) | 6 (4 to 8) | 1.27 (1.15 to 1.40) | 666 (14) | 4 (2 to 5) | 1.45 (1.32 to 1.59) | |
| Surgery | |||||||
| Calendar period | 1990–1994 | 126 (11) | 22 (15 to 29) | 2.02 (1.56 to 2.61) | 346 (31) | 20 (15 to 24) | 2.03 (1.56 to 2.63) |
| 1995–1999 | 191 (17) | 29 (22 to 35) | 1.46 (1.16 to 1.83) | 275 (25) | 25 (20 to 31) | 1.62 (1.24 to 2.13) | |
| 2000–2004 | 275 (24) | 27 (21 to 32) | 1.45 (1.18 to 1.79) | 183 (16) | 25 (18 to 31) | 1.53 (1.15 to 2.04) | |
| 2005–2009 | 277 (24) | 38 (32 to 43) | 1.07 (0.86 to 1.33) | 193 (17) | 29 (23 to 35) | 1.41 (1.06 to 1.88) | |
| 2010–2013 | 262 (23) | 40 (34 to 46) | 1 (reference) | 119 (11) | 39 (30 to 48) | 1 (reference) | |
| Age (years) | <60 | 286 (25) | 40 (35 to 46) | 1 (reference) | 317 (28) | 25 (20 to 30) | 1 (reference) |
| 60–69 | 423 (37) | 31 (26 to 35) | 1.25 (1.03 to 1.51) | 443 (40) | 28 (24 to 32) | 1.00 (0.85 to 1.19) | |
| 70–79 | 370 (33) | 30 (25 to 34) | 1.28 (1.05 to 1.56) | 328 (29) | 24 (19 to 29) | 1.13 (0.94 to 1.35) | |
| ≥80 | 52 (5) | 15 (5 to 24) | 1.98 (1.41 to 2.77) | 28 (3) | 11 (−1 to 22) | 1.61 (1.07 to 2.45) | |
| Sex | Male | 987 (87) | 31 (28 to 34) | 1 (reference) | 729 (65) | 21 (18 to 24) | 1 (reference) |
| Female | 144 (13) | 37 (29 to 45) | 0.84 (0.68 to 1.05) | 387 (35) | 33 (29 to 38) | 0.71 (0.61 to 0.83) | |
| Comorbidity score | 0 | 733 (65) | 33 (29 to 36) | 1 (reference) | 698 (63) | 27 (24 to 31) | 1 (reference) |
| 1 | 299 (26) | 32 (27 to 38) | 1.05 (0.89 to 1.23) | 340 (30) | 23(18-27) | 1.13 (0.97 to 1.31) | |
| ≥2 | 99 (9) | 26 (18 to 36) | 1.19 (0.93 to 1.53) | 78 (7) | 22 (12 to 31) | 1.20 (0.92 to 1.57) | |
| No surgery | |||||||
| Calendar period | 1990–1994 | 206 (8) | 3 (0 to 5) | 1.10 (0.94 to 1.29) | 802 (23) | 2 (1 to 3) | 1.24 (1.11 to 1.39) |
| 1995–1999 | 366 (14) | 1 (0 to 2) | 1.14 (1.00 to 1.30) | 739 (21) | 4 (2 to 5) | 1.15 (1.02 to 1.28) | |
| 2000–2004 | 585 (22) | 4 (2 to 6) | 1.02 (0.91 to 1.13) | 748 (21) | 3 (2 to 5) | 1.06 (0.95 to 1.19) | |
| 2005–2009 | 777 (29) | 3 (2 to 5) | 1.00 (0.90 to 1.11) | 668 (19) | 4 (3 to 6) | 1.06 (0.95 to 1.19) | |
| 2010–2013 | 729 (27) | 3 (2 to 5) | 1 (reference) | 558 (16) | 5 (3 to 7) | 1 (reference) | |
| Age (years) | <60 | 400 (15) | 3 (1 to 4) | 1 (reference) | 470(13) | 7 (5 to 9) | 1 (reference) |
| 60–69 | 656 (25) | 6 (4 to 7) | 0.91 (0.80 to 1.04) | 901 (26) | 4 (3 to 5) | 1.07 (0.95 to 1.20) | |
| 70–79 | 796 (30) | 3 (2 to 4) | 1.05 (0.93 to 1.19) | 1260 (36) | 4 (3 to 5) | 1.19 (1.06 to 1.32) | |
| ≥80 | 811 (30) | 1 (0 to 2) | 1.21 (1.06 to 1.37) | 884 (25) | 1 (1 to 2) | 1.42 (1.26 to 1.60) | |
| Sex | Male | 2111 (79) | 3 (2 to 4) | 1 (reference) | 2209 (63) | 3 (2 to 4) | 1 (reference) |
| Female | 552 (21) | 3 (1 to 4) | 1.00 (0.90 to 1.10) | 1306 (37) | 4 (3 to 5) | 0.86 (0.81 to 0.93) | |
| Comorbidity score | 0 | 1363 (51) | 4 (3 to 5) | 1 (reference) | 1669 (47) | 5 (4 to 6) | 1 (reference) |
| 1 | 816 (31) | 3 (1 to 4) | 1.04 (0.95 to 1.14) | 1258 (36) | 3 (2 to 4) | 1.07 (0.99 to 1.15) | |
| ≥2 | 484 (18) | 2 (0 to 3) | 1.08 (0.97 to 1.20) | 588 (17) | 1 (0 to 2) | 1.30 (1.18 to 1.43) | |
*Adjusted for calendar period, age, sex and comorbidity.